Free Trial

Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story

→ 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad)

Walgreens Stock price

Key Points

  • Walgreens Boots Alliance has better than expected quarter despite the loss of COVID sales. 
  • The growth outlook is getting better, and analysts see upside ahead. 
  • The stock yields more than 5.5% and may be too good to pass up. 
  • 5 stocks we like better than Walgreens Boots Alliance

Walgreens Boots Alliance NASDAQ: WBA is an alluring buy, with the stock trading at only 7.5X earnings and paying more than 5.75% in yield. This combination is among the best in a blue chip stock, and the dividend is safe for now. The other story driving the value of this stock is the turnaround story. The turnaround story has been dragging on for years and still faces headwinds. The passing of COVID is a significant headwind that has cut deeply into the bottom line. However, the takeaway from the Q2 report is promising. The company is about to lap the worst of the COVID comparisons and is on track to begin growing earnings again. 

"WBA exited a solid second quarter with acceleration in February, adding to our confidence in driving strong growth in the second half of the year. With the closing of VillageMD's acquisition of Summit Health, WBA is now one of the largest players in primary care, with best-in-class assets across the care continuum … We will continue to take bold actions to create sustainable long-term shareholder value,” said CEO Rosalind Brewer. 

Walgreens Has Good Quarter Despite Headwinds 

Walgreens had an excellent Q2 despite the drag of declining COVID activity on the business. The company reported $34.9 billion in net revenue for a gain of 3.3% over the last year. The revenue beat the consensus figure by 50 basis points, including the impacts of FX. On a segment basis, US Retail Pharmacy was the weakest with a -0.3% decline due to a -1.8% decline in retail sales. The International segment saw a robust 9% organic increase, 1.6% after FX conversion, and the US Health segment was even more substantial. US Health grew more than double due to acquisition and is nearly 5% of the business. 

Margin is a mixed bag of news, with GAAP results negative and adjusted results positive. The reason is one-off charges related to opioid settlements, the acquisition of Summit Health and restructuring are at play. Those aside, the company’s strong FCF can sustain the dividend.  Regarding the earnings, adjusted EPS of $1.16 is down 27% YOY, but 26% is due to COVID. The more important detail is that EPS beat by a nickel, and the guidance is positive. 

Walgreens is expecting full-year adjusted EPS of $4.45 to $4.65 compared to the $4.50 expected by the analysts. The company is forecasting earnings growth in the mid-20% for the 2nd half because of momentum in core operations and the passing of tough comps relative to last year. These figures include expected investment which should help sustain growth into the following year. 

Analyst Predict Rebound For Walgreens Share Price

The analysts have trimmed their estimates for the last year, but the trend has ended. Marketbeat hasn’t picked up any new reports yet, but the consensus target hit bottom last quarter and has trended flat since then. The point is that consensus is about 30% above the current price action and has the stock trading at the top of a range and in a position to break out, given the proper catalyst. 

→ The Worst is Yet to Come… (From Porter & Company) (Ad)

Should you invest $1,000 in Walgreens Boots Alliance right now?

Before you consider Walgreens Boots Alliance, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Walgreens Boots Alliance wasn't on the list.

While Walgreens Boots Alliance currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Walgreens Boots Alliance (WBA)
4.7097 of 5 stars
$14.99-2.5%6.67%-2.14Reduce$24.36
Compare These Stocks  Add These Stocks to My Watchlist 

Thomas Hughes

About Thomas Hughes

  • tmhughes.writeon@gmail.com

Contributing Author

Technical and Fundamental Analysis

Experience

Thomas Hughes has been a contributing writer for MarketBeat since 2019.

Areas of Expertise

Technical analysis, the S&P 500; retail, consumer, consumer staples, dividends, high-yield, small caps, technology, economic data, oil, cryptocurrencies

Education

Associate of Arts in Culinary Technology

Past Experience

Market watcher, trader and investor for numerous websites. Founded Passive Market Intelligence LLC to provide market research insights. 


Featured Articles and Offers

Micron Stock is the NVIDIA of Memory

Micron Stock is the NVIDIA of Memory

Micron is at an inflection point for the business and the stock price. End-market inventory normalization and AI have allowed the company to return to growth, with growth accelerating to 50% last quar

Search Headlines: